journal
MENU ▼
Read by QxMD icon Read
search

Future Oncology

journal
https://www.readbyqxmd.com/read/28095720/baseline-chromogranin-a-and-its-dynamics-are-prognostic-markers-in-gastroenteropancreatic-neuroendocrine-tumors
#1
Wojciech Rogowski, Ewa Wachuła, Anna Lewczuk, Agnieszka Kolesińska-Ćwikła, Ewa Iżycka-Świeszewska, Violetta Sulżyc-Bielicka, Jarosław B Ćwikła
AIM: This study assessed whether absolute chromogranin A (CgA) values at various stages of treatment have prognostic value in patients with pancreatic and midgut neuroendocrine tumors, subjected to peptide receptor radionuclide therapy with (90)Y-[DOTA(0), D-Phe(1), Tyr(3)]-octreotate. PATIENTS & METHODS: CgA was determined before peptide receptor radionuclide therapy, 6 weeks, 6, 12, 18 and 24 months after the last dose of (90)Y-[DOTA(0), D-Phe(1), Tyr(3)]-octreotate...
January 18, 2017: Future Oncology
https://www.readbyqxmd.com/read/28095710/the-evolving-role-of-chemotherapy-in-prostate-cancer
#2
Suliman Boulos, Danish Mazhar
Despite extensive clinical research of different chemotherapy agents for more than three decades, the role of chemotherapy in prostate cancer was only established in 2004, after demonstrating a survival benefit with docetaxel in metastatic castration-resistant prostate cancer. 6 years later, second-line chemotherapy using cabazitaxel, after disease progression on docetaxel, demonstrated an additional survival improvement. Recently, docetaxel given alongside standard hormonal therapy in newly diagnosed advanced prostate cancer was found to lead to significantly improved patient outcomes...
January 18, 2017: Future Oncology
https://www.readbyqxmd.com/read/28095701/malignant-bowel-obstruction-in-advanced-ovarian-cancer
#3
Emma Dean, Leila Khoja, Andrew Clamp, Gordon C Jayson, Dilly Goonetilleke, Alicia M Conway, Jurjees Hasan
AIM: Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood. METHODS: This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO. RESULTS: At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0...
January 18, 2017: Future Oncology
https://www.readbyqxmd.com/read/28092982/second-malignancy-risk-in-prostate-cancer-and-radiotherapy
#4
Tomer Charas, Amandeep Taggar, Michael J Zelefsky
No abstract text is available yet for this article.
January 17, 2017: Future Oncology
https://www.readbyqxmd.com/read/28088872/prognostic-prediction-by-liver-tissue-proteomic-profiling-in-patients-with-colorectal-liver-metastases
#5
Adalgiza Reyes, Josep Marti, Santiago Marfà, Wladimiro Jiménez, Vedrana Reichenbach, Amalia Pelegrina, Constantino Fondevila, Juan Carlos Garcia Valdecasas, Josep Fuster
AIM: To obtain proteomic profiles in patients with colorectal liver metastases (CRLM) and identify the relationship between profiles and the prognosis of CRLM patients. MATERIALS & METHODS: Prognosis prediction (favorable or unfavorable according to Fong's score) by a classification and regression tree algorithm of surface-enhanced laser desorption/ionization TOF-MS proteomic profiles from cryopreserved CRLM (patients) and normal liver tissue (controls). RESULTS: The protein peak 7371 m/z showed the clearest differences between CRLM and control groups (94...
January 16, 2017: Future Oncology
https://www.readbyqxmd.com/read/28088868/prognostic-values-of-ki-67-in-neoadjuvant-setting-for-breast-cancer-a-systematic-review-and-meta-analysis
#6
Lun Li, Dongdong Han, Xiaowei Wang, Quan Wang, Jinhui Tian, Jia Yao, Liqin Yuan, Ke Qian, Qiongyan Zou, Wenjun Yi, Enxiang Zhou, Kehu Yang
AIM: To assess the prognostic values of Ki-67 in neoadjuvant setting for breast cancer patients. METHODS: PubMed and EMBASE were searched. Revman software was used to conduct random-effect model meta-analysis. RESULTS: 49 studies (14,076 patients) were included. High Ki-67 before and after neoadjuvant chemotherapy were associated with worse overall survival (OS; before: hazard ratio [HR]: 2.29; 95% CI: 1.42-3.69; after: HR: 2.24; 95% CI: 1...
January 16, 2017: Future Oncology
https://www.readbyqxmd.com/read/28076966/evesor-a-model-based-multiparameter-phase-i-trial-to-optimize-the-benefit-toxicity-ratio-of-everolimus-and-sorafenib
#7
Mévidette El-Madani, Olivier Colomban, Michel Tod, Denis Maillet, Julien Peron, Claire Rodriguez-Lafrasse, Osama A Badary, Pierre-Jean Valette, Thibaud Lefort, Philippe Cassier, Siham M El-Shenawy, Ebtehal El-Demerdash, Juliette Hommel-Fontaine, Jerome Guitton, Marie-Claude Gagnieu, Bassant Mm Ibrahim, Catherine Barrois, Gilles Freyer, Benoit You
AIM: This novel multiparameter Phase I study aimed to optimize doses/dosing schedules of everolimus and sorafenib drug combination, based on modeling/simulation (NCT01932177). PATIENTS & METHODS: About 26 patients with solid tumors were treated in four different dosing schedules. Everolimus once daily + sorafenib twice daily were given continuously in arms A and B, and intermittently in arms C (alternating every other week) and D (everolimus continuous and sorafenib 3 days on/4 days off)...
January 12, 2017: Future Oncology
https://www.readbyqxmd.com/read/28075171/the-role-of-tumor-microenvironment-in-collective-tumor-cell-invasion
#8
Jia-Shun Wu, Su-Rui Sheng, Xin-Hua Liang, Ya-Ling Tang
For many cancer types, cancer cells invade into surrounding tissues by collective movement of cell groups that remain connected via cell-cell junctions. This migration is completely distinguished from single-cell migration, in which cancer cells disrupt the tight intercellular junctions and gain a mesenchymal phenotype. Recently, emerging evidence has revealed that collective cell invasion depends on not only cell-intrinsic mechanisms but also on extracellular mechanisms by bidirectional interplay between the tumor cell and the tumor environment...
January 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/28075166/the-predictive-value-of-ki-67-before-neoadjuvant-chemotherapy-for-breast-cancer-a-systematic-review-and-meta-analysis
#9
Xianyu Chen, Chao He, Dongdong Han, Meirong Zhou, Quan Wang, Jinhui Tian, Lun Li, Feng Xu, Enxiang Zhou, Kehu Yang
AIM: To review the predictive values of Ki-67 before neoadjuvant chemotherapy (NAC) for breast cancer patients. METHODS: PubMed and EMBASE were searched. Random-effect model meta-analysis was conducted using Revman software. RESULTS: High Ki-67 was associated with more pathological complete responses (pCRs) events (odds ratio: 3.10; 95% CI: 2.52-3.81; 53 studies, 10,848 patients) regardless of HR(+), HER2(+) and triple-negative breast cancer types, the definitions of pCR and cut-off points for Ki-67...
January 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/28073294/circulating-tumor-cells-and-dna-for-real-time-egfr-detection-and-monitoring-of-non-small-cell-lung-cancer
#10
Jinfeng He, Wei Tan, Jingping Ma
AIM: We investigate the suitability of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in non-small-cell lung cancer management, which is challenging in conventional biopsies. MATERIALS & METHODS: We performed serial blood extraction from 120 patients of varying EGFR status. Molecular profiling was performed using droplet digital PCR and correlated to survival outcome. RESULTS: Overall, we observed 95% agreement using CTCs and ctDNA with conventional tissue biopsies, which indicated the disease's close correlation...
January 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/28067073/translating-genomic-profiling-to-gastrointestinal-cancer-treatment
#11
Kazuto Harada, Dilsa Mizrak Kaya, Yusuke Shimodaira, Shumei Song, Hideo Baba, Jaffer A Ajani
Next-generation sequencing enables faster, cheaper and more accurate whole-genome sequencing, allowing genome profiling and discovery of molecular features. As molecular targeted drugs are developed, treatment can be tailored according to molecular subtype. Gastric and colorectal cancers have each been divided into four subtypes according to molecular features. Profiling of the esophageal cancer genome is underway and its classification is anticipated. To date, identification of HER2 expression in gastric adenocarcinoma and KRAS, NRAS and BRAF mutations in colon cancer have proved essential for treatment decisions...
9, 2017: Future Oncology
https://www.readbyqxmd.com/read/28067056/potential-benefit-of-rotational-radiation-therapy
#12
Jason Vickress, Michael Lock, Simon Lo, Slav Yartsev
No abstract text is available yet for this article.
January 9, 2017: Future Oncology
https://www.readbyqxmd.com/read/28052691/strategies-to-prevent-peritoneal-carcinomatosis-arising-from-colorectal-cancer
#13
Maximiliano Gelli, Janina Fl Hugueinin, Cecilia Cerebelli, Léonor Benhaim, Charles Honoré, Dominique Elias, Diane Goéré
In the last decades, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy became a curative option for peritoneal metastases in selected patients, otherwise considered for palliative therapy alone. Better knowledge of physiopathology of peritoneal spread and identification of predictive factors for peritoneal relapse prompted specialized centers to investigate the role of a 'proactive approach' in order to early detect peritoneal metastasis. These encouraging data could justify an active attitude in selected patients at high risk of peritoneal recurrence after curative resection of primary tumor...
January 5, 2017: Future Oncology
https://www.readbyqxmd.com/read/28052688/tert-promoter-mutation-status-in-sarcomatoid-urothelial-carcinomas-of-the-upper-urinary-tract
#14
Xiaoyan Wang, Antonio Lopez-Beltran, Adeboye O Osunkoya, Mingsheng Wang, Shaobo Zhang, Darrell D Davidson, Robert E Emerson, Sean R Williamson, Puay-Hoon Tan, Hristos Z Kaimakliotis, Lee Ann Baldridge, Gregory T MacLennan, Rodolfo Montironi, Liang Cheng
AIM: To determine TERT promoter mutation status as well as the expression of PAX8, GATA3, p63, p40, p53 and uroplakin III in 17 patients with the upper urinary tract sarcomatoid urothelial carcinoma. METHODS & RESULTS:  TERT C228T mutations were found in six of 17 cases (35%). p53 was expressed in 77% of these tumors. PAX8, GATA3, p40 and uroplakin III are less frequently expressed. Lymph node metastases were present in ten cases (59%). Eight patients (47%), including all three patients with TERT mutation, died of cancer within 2 years after surgery...
January 5, 2017: Future Oncology
https://www.readbyqxmd.com/read/28045335/phase-ii-trial-of-capecitabine-plus-erlotinib-versus-capecitabine-alone-in-patients-with-advanced-colorectal-cancer
#15
Mark D Vincent, Daniel Breadner, Denis Soulieres, Ian G Kerr, Michael Sanatani, Walter Kocha, Peter Klimo, Mary J MacKenzie, Anne O'Connell, Frances Whiston, Anne S Malpage, Larry Stitt, Stephen A Welch
: Aim & methods: Capecitabine monotherapy as palliation for advanced colorectal cancer (CRC) is generally well tolerated. Adding erlotinib, an EGFR-tyrosine kinase inhibitor, might improve efficacy versus capecitabine alone. 82 patients received capecitabine alone (Arm 1) or capecitabine with erlotinib (Arm 2). RESULTS: Median time-to-progression (TTP) in Arm 1 was 7.9 months versus 9.2 in Arm 2. In KRAS-wild type (WT) patients TTP was 8.4 and 11.7 months in Arms 1 and 2, respectively...
January 3, 2017: Future Oncology
https://www.readbyqxmd.com/read/27935324/outcomes-of-haploidentical-transplant-compared-with-matched-donor-allogeneic-stem-cell-transplant
#16
Janak Adhikari, Bishal Gyawali, Priyadarshani Sharma, Vijaya Raj Bhatt
The risk of acute and chronic graft-versus-host disease (GVHD) with haploidentical transplant with post-transplant high-dose cyclophosphamide may be lower compared with matched unrelated donor transplant and largely similar to matched related donor transplant. The lower probability of GVHD with the haploidentical donor may result in a risk of nonrelapse mortality that is at least similar to or even lower than the matched donor. The incidence of relapse and survival are also largely similar to different donor types...
December 9, 2016: Future Oncology
https://www.readbyqxmd.com/read/27928934/letter-in-reply-to-fertility-preservation-before-an-abvd-protocol-no-new-evidence-to-support-changing-the-recommendations
#17
Charlotte Sonigo, Nathalie Sermondade, Michaël Grynberg
No abstract text is available yet for this article.
December 8, 2016: Future Oncology
https://www.readbyqxmd.com/read/27924638/understanding-sarcomas-and-other-rare-tumors-an-interview-with-robin-l-jones
#18
Robin L Jones
Robin Jones speaks to Jade Parker, Commissioning Editor: Robin Jones is a medical oncologist specializing in the treatment of bone and soft tissue sarcomas and Head of the Sarcoma Unit at The Royal Marsden. He completed his medical training at Guy's and St Thomas' Hospital, and his oncology training at The Royal Marsden. His postgraduate research degree, with Professor Dowsett at the Institute of Cancer Research (ICR), evaluated potential predictive and prognostic factors in breast cancer patients treated with neoadjuvant chemotherapy...
December 7, 2016: Future Oncology
https://www.readbyqxmd.com/read/27921440/fertility-preservation-before-an-abvd-protocol-no-new-evidence-to-support-changing-the-recommendations
#19
Catherine Poirot, Nathalie Dhedin, Pauline Brice
No abstract text is available yet for this article.
December 6, 2016: Future Oncology
https://www.readbyqxmd.com/read/27908206/the-role-of-mesenchymal-stem-cells-in-oncology-and-regenerative-medicine
#20
Maliha Khan, Syeda Ezze Rukhshan Adil, Amanda L Olson
Mesenchymal stem cells (MSCs) have long been used as therapeutic agents in disease affecting various organ systems. However, MSCs are fast emerging as promising anticancer agents which have the potential to treat a number of different cancer types, including glioblastoma and metastatic breast, ovarian and hepatic carcinoma. The ability of MSC to migrate directly into the tumor microenvironment and to produce IFN-α and -β makes this possible. However, the possibility of MSC undergoing either malignant transformation or transformation into protumorigenic fibroblasts currently limits their role in clinical use...
December 2, 2016: Future Oncology
journal
journal
41162
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"